临床医学研究与实践2023年3月第8卷第7期Valueofsecond-generationgenesequencingtechnologyindetectingCRLF2,FLT3andC-KITmutationinpatientswithacutemyeloidleukemiaCHANGYuanyuan,YANGYafeng*(HematologyDepartment,YulinNo.2Hospital,Yulin719000,China)ABSTRACT:ObjectiveToexplorethevalueofsecond-generationgenesequencingtechnologyindetectingcytokinereceptorlikefactor2(CRLF2),FMS-liketyrosinekinase3(FLT3)andC-KITmutationinpatientswithacutemyeloidleukemia.MethodsAtotalof78patientswithacutemyeloidleukemiatreatedinourhospitalfromJanuary2017toJanuary2020wereselectedastheresearchobjects.TheCRLF2,FLT3andC-KITmutationweredetectedbysecond-generationgenesequencingtechnology.TheclinicalparametersofpatientswithdifferentmutationtypesofCRLF2,FLT3andC-KITwerecompared;thecompleteremissionrateaftertreatmentfor≤2coursesandrecurrencerateofpatientswithdifferentmutationtypesofCRLF2,FLT3andC-KITwerecompared.ResultsTherewere11casesofCRLF2mutationin78patients,withamutationrateof14.10%,themutationrateofnormalkaryotypewashigherthanthatofabnormalkaryotype,andthedifferencewasstatisticallysignificant(P<0.05);therewere9casesofFLT3mutation,withamutationrateof11.54%,themutationrateofnormalkaryotypewashigherthanthatofabnormalkaryotype,andthedifferencewasstatisticallysignificant(P<0.05);therewere6casesofC-KITmutation,withamutationrateof7.69%,themutationrateofnormalkaryotypewaslowerthanthatofabnormalkaryotype,andthedifferencewasstatisticallysignificant(P<0.05).Thereweresignificantdifferencesinage,whitebloodcellcountandplateletcountamongpatientswithdifferentmutationtypesofCRLF2(P<0.05);therewassignificantdifferenceinwhitebloodcellcountamongpatientswithdifferentmutationtypesofFLT3(P<0.05);therewassignificantdifferenceinhemoglobinlevelamongpatientswithdifferentmutationtypesofC-KIT(P<0.05).Atotalof76patientswerefolloweduptoevaluatetheinterventioneffect.Therewerenostatisticallysignificantdifferencesinthecompleteremissionrateaftertreatmentfor≤2coursesandrecurrencerateofpatientswithdifferentmutationtypesofCRLF2(P>0.0...
